Recant L, Perrino P V, Bhathena S J, Danforth D N, Lavine R L
Diabetologia. 1976 Aug;12(4):319-26. doi: 10.1007/BF00420975.
Immunoreactive glucagon (IRG) fractions from plasma of 8 normal subjects and 4 patients with glucagon secreting tumors were studied by gel filtration techniques on Bio Gel P--30 and Sephadex G--50 columns. The pancreatic glucagon specific anti serum (30K) of Unger was utilized to measure IRG. Columns were calibrated with labelled albumin, proinsulin, insulin and glucagon. Four peaks were defined in normal and tumor bearing patients: peak I (greater than 20 000 mol. wt.), peak II (primarily 9000 mol. wt.), peak III pancreatic glucagon (3500 mol. wt.) and peak IV small gucagon (less than 3500 mol. wt.). Glucagonoma patients differed from our normal and reported normal subjects in that peak II contained most of the circulating IRG. The percent of IRG associated with peak II was 9.5--31.5% in normals and 39.1--61.2% in glucagonomas. Glucagon-like biological activity in an isolated hepatocyte system was demonstrated for all peaks. However, relative to immunoreactivity, peak II showed reduced activity (25--33%). Immunoassay of dilutions of all peaks revealed the probability of immuno determinants identical with procine pancreatic glucagon. The presence of heterogenous IRG peaks with biological glucagon-like activity suggest that the larger molecules may be prohormones. Further, it is possible that specific elevation of peak II may be a diagnostic feature of glucagonomas.
采用Bio Gel P - 30和Sephadex G - 50柱凝胶过滤技术，对8名正常受试者和4名胰高血糖素分泌肿瘤患者血浆中的免疫反应性胰高血糖素（IRG）组分进行了研究。利用昂格尔的胰腺胰高血糖素特异性抗血清（30K）来测定IRG。用标记的白蛋白、胰岛素原、胰岛素和胰高血糖素对柱子进行校准。在正常人和肿瘤患者中均确定了四个峰：峰I（分子量大于20000）、峰II（主要为9000分子量）、峰III胰腺胰高血糖素（3500分子量）和峰IV小胰高血糖素（分子量小于3500）。胰高血糖素瘤患者与我们的正常受试者及已报道的正常受试者不同之处在于，峰II包含了大部分循环中的IRG。正常受试者中与峰II相关的IRG百分比为9.5% - 31.5%，而在胰高血糖素瘤患者中为39.1% - 61.2%。在分离的肝细胞系统中，所有峰均表现出胰高血糖素样生物活性。然而，相对于免疫反应性而言，峰II的活性有所降低（25% - 33%）。对所有峰的稀释液进行免疫测定显示，存在与猪胰腺胰高血糖素相同的免疫决定簇。具有胰高血糖素样生物活性的异质性IRG峰的存在表明，较大的分子可能是前激素。此外，峰II的特异性升高可能是胰高血糖素瘤的一个诊断特征。
